168 related articles for article (PubMed ID: 34732618)
1. [Down syndrome and acute lymphoblastic leukemia].
Okamoto Y
Rinsho Ketsueki; 2021; 62(10):1465-1473. PubMed ID: 34732618
[TBL] [Abstract][Full Text] [Related]
2. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
[TBL] [Abstract][Full Text] [Related]
3. Gain of chromosome 21 increases the propensity for
Page EC; Heatley SL; Rehn J; Thomas PQ; Yeung DT; White DL
Front Oncol; 2023; 13():1177871. PubMed ID: 37483494
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
5. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
6. The acute lymphoblastic leukemia of Down Syndrome - Genetics and pathogenesis.
Izraeli S
Eur J Med Genet; 2016 Mar; 59(3):158-61. PubMed ID: 26631987
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients.
Page EC; Heatley SL; Yeung DT; Thomas PQ; White DL
Cancer Lett; 2018 Sep; 432():69-74. PubMed ID: 29879498
[TBL] [Abstract][Full Text] [Related]
8. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
[TBL] [Abstract][Full Text] [Related]
9. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.
Buitenkamp TD; Pieters R; Gallimore NE; van der Veer A; Meijerink JP; Beverloo HB; Zimmermann M; de Haas V; Richards SM; Vora AJ; Mitchell CD; Russell LJ; Schwab C; Harrison CJ; Moorman AV; van den Heuvel-Eibrink MM; den Boer ML; Zwaan CM
Leukemia; 2012 Oct; 26(10):2204-11. PubMed ID: 22441210
[TBL] [Abstract][Full Text] [Related]
10. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.
Ensor HM; Schwab C; Russell LJ; Richards SM; Morrison H; Masic D; Jones L; Kinsey SE; Vora AJ; Mitchell CD; Harrison CJ; Moorman AV
Blood; 2011 Feb; 117(7):2129-36. PubMed ID: 21106984
[TBL] [Abstract][Full Text] [Related]
11. Clinical, biological, and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
Wang Y; Li J; Xue TL; Tian S; Yue ZX; Liu SG; Gao C
Eur J Haematol; 2023 Jun; 110(6):669-679. PubMed ID: 36814093
[TBL] [Abstract][Full Text] [Related]
12. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.
Junco JJ; Zorman B; Gant VU; Muñoz J; Lacorazza HD; Sumazin P; Rabin KR
Exp Hematol; 2022 Jun; 110():34-38. PubMed ID: 35306048
[TBL] [Abstract][Full Text] [Related]
13. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
[TBL] [Abstract][Full Text] [Related]
14. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
Maloney KW; Carroll WL; Carroll AJ; Devidas M; Borowitz MJ; Martin PL; Pullen J; Whitlock JA; Willman CL; Winick NJ; Camitta BM; Hunger SP
Blood; 2010 Aug; 116(7):1045-50. PubMed ID: 20442364
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].
Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):311-315. PubMed ID: 33812392
[TBL] [Abstract][Full Text] [Related]
16. High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.
Lundin C; Hjorth L; Behrendtz M; Nordgren A; Palmqvist L; Andersen MK; Biloglav A; Forestier E; Paulsson K; Johansson B
Genes Chromosomes Cancer; 2012 Feb; 51(2):196-206. PubMed ID: 22072402
[TBL] [Abstract][Full Text] [Related]
17. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
Buitenkamp TD; Izraeli S; Zimmermann M; Forestier E; Heerema NA; van den Heuvel-Eibrink MM; Pieters R; Korbijn CM; Silverman LB; Schmiegelow K; Liang DC; Horibe K; Arico M; Biondi A; Basso G; Rabin KR; Schrappe M; Cario G; Mann G; Morak M; Panzer-Grümayer R; Mondelaers V; Lammens T; Cavé H; Stark B; Ganmore I; Moorman AV; Vora A; Hunger SP; Pui CH; Mullighan CG; Manabe A; Escherich G; Kowalczyk JR; Whitlock JA; Zwaan CM
Blood; 2014 Jan; 123(1):70-7. PubMed ID: 24222333
[TBL] [Abstract][Full Text] [Related]
18. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.
Lee P; Bhansali R; Izraeli S; Hijiya N; Crispino JD
Leukemia; 2016 Sep; 30(9):1816-23. PubMed ID: 27285583
[TBL] [Abstract][Full Text] [Related]
19. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Papayannidis C; Candoni A; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci C; Rambaldi A; Guarini A; Bassan R; Foà R
Haematologica; 2021 Jun; 106(6):1559-1568. PubMed ID: 32467145
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia.
Dou H; Chen X; Huang Y; Su Y; Lu L; Yu J; Yin Y; Bao L
Genes Chromosomes Cancer; 2017 Feb; 56(2):135-146. PubMed ID: 27637012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]